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S U M M A R Y
Background: Protein antigens comprising peptide motifs with high binding afﬁnity to major
histocompatibility complex class I (MHC-I) molecules are expected to induce a stronger cytotoxic
T-lymphocyte response and thus provide better protection against infection with microorganisms where
cytotoxic T-cells are the main effector arm of the immune system.
Methods: Data on cyst formation and survival were extracted from past studies on the DNA
immunization of mice with plasmids coding for Toxoplasma gondii antigens. From in silico analyses
of the vaccine antigens, the correlation was tested between the predicted afﬁnity for MHC-I molecules of
the vaccine peptides and the survival of immunized mice after challenge with T. gondii. ELISPOT analysis
was used for the experimental testing of peptide immunogenicity.
Results: Predictions for the Db MHC-I molecule produced a strong, negative correlation between survival
and the dissociation constant of vaccine-derived peptides. The in silico analyses of nine T. gondii antigens
identiﬁed peptides with a predicted dissociation constant in the interval from 10 nM to 40 mM. ELISPOT
assays with splenocytes from T. gondii-infected mice further supported the importance of the peptide
afﬁnity for MHC-I.
Conclusions: In silico analysis clearly helped the search for protective vaccine antigens. The ELISPOT
analysis conﬁrmed that the predicted T-cell epitopes were immunogenic by their ability to release
interferon gamma in spleen cells.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The adaptive immune response is initiated by T-cells recogniz-
ing peptides displayed on the cell surface of antigen-presenting
cells (APCs) by major histocompatibility complex (MHC) mole-
cules.1 MHC class I (MHC-I) molecules mainly present peptides
originating from intracellular proteolysis to CD8+ T-cells, also
known as cytotoxic T-lymphocytes (CTLs). MHC class II molecules
present extracellular peptides to CD4+ T-cells (helper T-cells).2 For
intracellular microorganisms, including the parasite Toxoplasma
gondii, the CTL response is the key effector arm of the immune
system for protective immunity and is elicited by small linear
epitopes from processed antigens.1* Corresponding author.
E-mail address: vorup-jensen@biomed.au.dk (T. Vorup-Jensen).
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1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Advances in both computational and experimental approaches
have enabled the afﬁnity of the binding between the MHC-I
molecule and the peptide to be largely predicted in silico based on
the amino acid sequence of the peptide.3,4 These methods predict
binding with high accuracy for many alleles of MHC molecules and
integrate both proteasomal cleavage and transport events;5 they
are therefore suitable to select immunogenic epitopes.5,6 Peptide
predicting methods have been used previously to investigate the
immune response induced by different pathogens, such as
hepatitis B virus (HBV) and T. gondii.3,7
T. gondii is an obligate intracellular apicomplexan parasite
capable of infecting all warm-blooded animals, including humans.
It is estimated that one-third of the human world population is
infected with this parasite.8 After infection, the parasite evades the
immune system by forming cysts in muscle and nervous tissues,
such as the brain and retina. The host remains infected for life and
T. gondii is therefore an appropriate model for chronic, persistingciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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signiﬁcant human pathogens such as Plasmodium, HBV, hepatitis
C virus (HCV), HIV, Cryptosporidium, and Neospora.9 Of interest in
this context, the complete sequencing of the genomes of the
predominant strains of T. gondii along with the development of
predictive binding algorithms for peptide binding to MHC-I
peptides now offers the opportunity for rational vaccine develop-
ment based on epitope prediction.10 However, studies looking at
the correlation between the protection induced by a certain
peptide comprising a potential T-cell epitope from a pathogen and
the same peptide’s predicted afﬁnity for MHC molecules are
lacking.
The identiﬁcation of epitopes as small linear peptides is of key
importance for the rational design of CTL-stimulating vaccines
against T. gondii.11–15 Resistance to encephalitis in mice infected
with type II strains of T. gondii has been linked to the Ld region of
the MHC-I gene. This indicates that the peptides presented on
MHC-I and their interactions with CTLs are of critical importance.3
Peptides with a length of 8–11 residues and their predicted
binding to the MHC-I molecules were the focus of the present
study. In silico methods were used to estimate the binding afﬁnity
of peptides to MHC-I and thereby to predict potential T-cell
epitopes. The results were correlated to those of past studies
reporting on vaccine protection in a mouse model of infection with
T. gondii and data from the present study on the T-cell reactivity of
splenocytes from infected animals. It was found that the algorithm
is efﬁcient in identifying antigens protecting against animal death
from the infection as well as peptides that are immunoreactive.
2. Methods
2.1. Data extraction from past studies
PubMed was searched for studies on immune protection after
immunization or natural infection with proteins or plasmids from
T. gondii. The data were divided into groups according to the type of
antigen, the method of immunization, and the congenic mouse
strain, respectively (Table 1). Since the focus was on predictions of
CD8+ T-cell reactivity through the presentation of intracellular
synthesized antigens on MHC-I molecules, data from studies on
antigens delivered by DNA immunization were selected for further
study.
2.2. In silico prediction of the MHC-I afﬁnity for peptide epitopes
NetMHC 3.2 software was used (http://www.cbs.dtu.dk/
services/; accessed October 14, 2014), which integrates a
combination of artiﬁcial neural networks (ANNs) and weight
matrices to predict the afﬁnity of each epitope.4 The afﬁnity for all
8-, 9-, and 10-mer peptides found in nine vaccine antigens from
T. gondii (SAG1, GRA4, MIC2, AMA1, BAG1, M2AP, GRA1, GRA7, andTable 1
Antigens used for immunization in C57BL/6 mice
Antigen Size
(aa)
Antigen
vector
Mouse
strain
Antigen
delivery
Cyst
reduction (%)
SAG1 319 Plasmid C57BL/6 im 70 
GRA4 345 Plasmid C57BL/6 im NA 
MIC2 769 Plasmid C57BL/6 id NA 
AMA1 569 Plasmid C57BL/6 id NA 
BAG1 229 Plasmid C57BL/6 id NA 
M2AP 330 Plasmid C57BL/6 id NA 
GRA1 190 Plasmid C57BL/6 im NA 
GRA7 236 Plasmid C57BL/6 im NA 
ROP2 257 Plasmid C57BL/6 im NA 
aa, amino acids; im, intramuscular; id, intradermal; NA, not applicable.ROP2) was predicted for binding to the MHC-I molecules H2-Db
and H2-Kb, corresponding to the tissue type of the C57BL/6 mouse
strain. These values were used to construct a database tabulating
each peptide and the corresponding dissociation constant (KD)
value for both the H2-Db and H2-Kb molecules (data not shown).
2.3. In silico prediction of proteasome-resistant epitopes
PAProC is a prediction tool for cleavage by human and yeast
proteasomes, based on experimental cleavage data (http://www.
paproc.de/; accessed October 14, 2014).16 Because the proteases
are highly conserved between mice and humans,16 PAProC
software was used to predict the survival of peptides digested
by human proteasome for presentation on murine MHC-I. The
resistant peptides were also analyzed as 8-, 9-, and 10-mers and
tabulated as mentioned above.
2.4. Protein structure and prediction of epitopes
The structures of AMA1, MIC2, SAG1, and ROP2 T. gondii
proteins, as determined by X-ray crystallography, were obtained
from the Protein Data Bank: AMA1 (accession code 2X2Z), MIC2
(accession code 2XGG), SAG1 (accession code 1YNT), and ROP2
(accession code 2W1Z). No crystallographic data were available for
BAG1, GRA1, GRA4, GRA7, and M2AP in the Protein Data Bank, so
the three-dimensional structures were predicted using Robetta
software (http://robetta.bakerlab.org/; accessed October 14,
2014).17 Peptides with the lowest and the predicted highest KD
values before proteasomal digestion and peptides with the lowest
predicted KD value after digestion were located in the structures
for structural comparison of these epitopes.
2.5. T. gondii infection in mice, and spleen harvest
C57BL/6 mice, 4–6 weeks old, were purchased from Tachonic
(Laven, Denmark) and kept in a light-controlled environment
(12:12 h light–dark cycle) at Aarhus University; the mice had
access to food and water ad libitum. The protocol was approved
by the Animal Experiments Authority, Danish Ministry of Justice
(J. No. 2005/561-1071).
The ME49 T. gondii strain was used and maintained by
intraperitoneal passage. Brain cysts obtained from the brains of
infected mice were used to infect other mice. Each mouse was
infected with 10 cysts by intraperitoneal route. After infection,
weight and mortality were monitored daily.
Mice were euthanized 30 days after infection. Spleens were
harvested, mashed, and pressed through a 70-mm screen to form a
single-cell homogeneous suspension. The erythrocytes were deplet-
ed with AKC buffer (160 mM NH4Cl, 10 mM KHCO3, 100 mM
ethylenediaminetetraacetic acid (EDTA)). The remaining splenocytes
were washed twice with RPMI medium and resuspended in completeSurvived/
control (%)
T. gondii challenge strains Reference
90–100/0 ME49 (II) tissue cysts, oral Angus et al., 2000
62/0 76K (II) tissue cysts, oral Desolme et al., 2000
37.5/0 Beverly (II) tissue cysts, oral Dautu et al., 2007
37.5/0 Beverly (II) tissue cysts, oral Dautu et al., 2007
12.5/0 Beverly (II) tissue cysts, oral Dautu et al., 2007
0/0 Beverly (II) tissue cysts, oral Dautu et al., 2007
0/0 IPB-G (II) tissue cysts, oral Vercammen et al., 2000
0/0 IPB-G (II) tissue cysts, oral Vercammen et al., 2000
0/0 IPB-G (II) tissue cysts, oral Vercammen et al., 2000
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(Invitrogen, ), 100 U/ml penicillin, 100 mg/ml streptomycin, and 10%
(v/v) fetal calf serum (FCS)) before use in subsequent in vitro assays.
2.6. Enzyme-linked immunospot (ELISPOT) assay
Twenty-two peptides from nine different T. gondii antigens and
with a range of predicted KD values from 10 nM to 40 mM were
selected for further study (Table 2). Peptides were custom-
synthesized by GL Biochem (Shanghai, China) at >95% (w/w)
purity in lyophilized form.
For ELISPOT assays, Millipore Multiscreen HA 54510 96-well
plates (Millipore, Bedford, MA, USA) were coated with 100 ml of
15 mg/ml anti-mouse interferon gamma (IFN-g) monoclonal anti-
body (mAb) in sterile coating buffer overnight at 4 8C. Wells were
washed with sterile coating buffer and blocked with RPMI-1640
medium containing 10% FCS at room temperature for 2–3 h.
Splenocytes were then plated in complete RPMI-1640 medium at
5  105 cells per well. Peptides were added to each well at 10 mg/ml,
3 mg/ml, and 1 mg/ml, respectively, and plates were incubated at
37 8C with 5% CO2 for 48 h. Medium containing an equivalent
concentration of phosphate buffered saline (PBS) was used to
measure background response levels. Five micrograms per milliliter
of T. gondii lysate antigen (TLA) and 2.5 mg/ml concavalin A were
used as positive controls, and PBS only (without any peptides) was
used as a negative control. Plates were successively incubated with
100 ml anti-human IFN-g mAb for 2 h and avidin–horseradish
peroxidase (HRP) for 45 min at room temperature. Spots were
developed using freshly prepared 3-amino-9-ethyl carbazole (AEC)
for 10–60 min. The reaction was stopped with distilled water. Plates
were air-dried overnight at 4 8C, and spots were counted the next
day using an automated ELISPOT reader (CTL ImmunoSpot, Bonn,
Germany).
2.7. Statistical analyses
Statistical analyses were performed on the correlation between
the binding afﬁnity and the survival of the mice. p-Values and
correlation coefﬁcients were calculated using Prism 5.0 (GraphPad
Software, La Jolla, CA). p-Values of 0.05 or less were consideredTable 2
Characterization of the 22 peptides selected for stimulation of spleen cells using
ELISPOT
Name Position Peptides KD (nM) Original protein
PT1 196 FAFKTVAM 267 AMA1
PT21 473 DEQNECGSN 48 968 AMA1
PT2 368 RNYGFYYV 10 AMA1
PT3 0 MICSIMGGL 8633 AMA1
PT4 25 ISPSGVCPM 124 BAG1
PT5 122 VEFDSKKKEM 11 344 BAG1
PT6 58 VDLEMMGNT 20 103 GRA1
PT7 105 GSPMNGGYYM 116 GRA4
PT8 175 VTPGYSGL 11 GRA4
PT9 146 ATYYHPAA 1255 GRA4
PT10 182 TVLGFAAL 21 GRA7
PT11 38 RNSDFFDGQA 13 552 GRA7
PT12 156 SSNDGSAL 8782 M2AP
PT13 86 IGIQNFRLV 157 MIC2
PT14 117 VTYSTDVHL 40 MIC2
PT15 97 FLHTFLMV 1646 MIC2
PT22 229 GCSGTSDD 40 121 MIC2
PT16 105 FQVSNILL 279 ROP2
PT17 93 ASLHHYGLVH 3566 ROP2
PT18 15 AAPTLMSFL 80 SAG1
PT19 20 MSFLLCGV 101 SAG1
PT20 185 LSAEGPTTM 1020 SAG1
KD, dissociation constant.signiﬁcant for the correlation between afﬁnity and protection.
Statistical analyses for all in vitro assays were performed using a
two-tailed Student t-test. If peptides induced IFN-g spot formation
from peripheral blood mononuclear cells (PBMCs) of infected mice
that was signiﬁcantly higher (p < 0.05) than that in the controls,
the peptides were considered immunogenic. All ELISPOT experi-
ments were replicated a minimum of three times.
3. Results
3.1. Protective immunity of nine T. gondii antigens from previous
studies
Four studies were identiﬁed in which plasmid-based DNA
immunizations were used. These studies applied nine various
antigens in the C57BL/6 mouse strain.18–21 The antigens used in the
studies were AMA1, BAG1, GRA1, GRA4, GRA7, M2AP, MIC2, ROP2,
and SAG1. The different adjuvants used in the various studies were
ignored. Information on antigen delivery, key end-points, and
T. gondii isolates used for challenge in the C57BL/6 strain mice is
summarized in Table 1.
To test post-hoc if current epitope identiﬁcation strategies
could explain the lack of induced protection for the chosen T. gondii
vaccine antigens, the NetMHC 3.2 algorithm22 was employed for
the prediction of MHC-I T-cell epitopes. The binding afﬁnities were
predicted for all of the 8-, 9-, and 10-mer peptides found in the nine
antigens. Calculations were done for the two MHC-I tissue types
(Kb and Db) carried by C57BL/6 mice.
The average KD value of peptides from the Kb tissue type was
lower than the average KD value from the Db tissue type, regardless
of the antigen (Figure 1). All peptides were compared according to
their KD value and the 10% with the lowest KD (i.e., highest afﬁnity)
for each tissue type were chosen for further analysis. A signiﬁcant
(p < 0.05) negative correlation was found between the KD value for
the peptides identiﬁed in the antigens used for immunization in
the Db tissue type and the protective immunity after immuniza-
tion and subsequent challenge with T. gondii, here enumerated as
the percentage of surviving animals (Figure 2). The vaccines used
were plasmid vaccines where the protein is synthesized in the
animal host cell. The predicted peptides were epitopes in
the speciﬁc protein. In contrast, there was no correlation between
the KD value for the peptides in the Kb tissue type and survival
(p = 0.47) (Figure 2).
3.2. In silico prediction of proteasome-resistant epitopes
Proteasomes digest proteins into peptides, which are presented
on MHC-I molecules. Obviously, this presents an obstacle for
analyses of peptides binding MHC-I, in that some of the well-
binding sequence may be destroyed by proteasomal degradation.
To correct for this potential problem, in silico predictions of
proteasomal cleavage were made. The PAProC algorithm16 was
applied to predict proteasomal cleavage by human and wild-type
or mutant yeast proteasomes. The inﬂuence of different amino
acids at different positions is determined using a stochastic hill-
climbing algorithm based on the experimentally veriﬁed in vitro
cleavage and non-cleavage sites. From these predicted protein
fragments, peptides sized between 8 and 10 amino acids were
chosen and their corresponding KD values, predicted with the
NetMHC 3.2 algorithm, were listed. Peptides that escaped
proteasomal digestion showed no correlation between their
predicted afﬁnity for the MHC-I Db tissue type and the protection
of animals measured by survival after immunization (p = 0.1). By
contrast, there was a signiﬁcant correlation in the case of the Kb
tissue type (p = 0.05).
Figure 1. Afﬁnity of peptides binding to MHC class I from two different tissue types of C57BL/6 strain mice: Kb and Db. The binding afﬁnity of each predicted peptide from the
nine antigens is shown, and the average KD for all peptides belonging to the same antigen is marked for both tissue types.
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The crystal structure of AMA1 included only residues 64–519.
MIC2 (residues 26–174), SAG1 (residues 50–303), and ROP2
(residues 195–561), as well as the predicted structures of BAG1,
GRA1, GRA4, GRA7, and M2AP, were all full-length. The location
and structure of the different peptides in the selected antigens are
shown in the Figure 3. There was no obvious relationship between
the structures of the peptides in the antigens and their KD values,nor was it possible to ﬁnd any connection to protective immunity
of the antigens.
3.4. Peptides elicit potent IFN-g production from PBMCs in vitro
IFN-g is the key mediator of protective immunity during both
the acute and chronic phases of T. gondii infection in mice.23 The
ability of 22 peptides to induce a speciﬁc IFN-g production in H-2b
mice was evaluated (Table 2). C57BL/6 (H-2b) mice were infected
Figure 2. Correlation between the KD value of peptides from nine different antigens and the protective immunity after immunization with corresponding antigens and
challenge with Toxoplasma gondii. Different symbols indicate different antigens. (A) Peptides in the Db tissue type; (B) peptides in the Kb tissue type; (C) surviving peptides
after digestion of the Db tissue type; (D) surviving peptides after digestion of the Kb tissue type. *: SAG1; *: GRA4; ~: AMA1; ~: MIC2; &: BAG1; *: ROP2; ^: GRA7; &:
M2AP; ^: GRA1.
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infection. The proportion of IFN-g secreting splenocytes induced
by the peptides and controls was measured and compared using an
ex vivo ELISPOT assay. Four peptides (PT7, PT8, PT17, and PT18)
elicited signiﬁcantly higher speciﬁc IFN-g production relative to
controls (Figure 4, p < 0.01), but there was no correlation between
the IFN-g production and the predicted binding afﬁnity of the
peptides to MHC-I.
4. Discussions
MHC-I molecules direct CTLs to destroy pathogen-infected or
cancerous cells, thereby preventing disease progression.24 In thisFigure 3. Structures of the nine antigens that have given rise to the investigated peptides. 
ROP2); (B) antigens without crystal structures in the Protein Data Bank (BAG1, GRA1, GR
section). The locations of the different peptides are marked on the structures of the diffe
peptides with the lowest afﬁnity in the Kb tissue type; blue: peptides with the highest a
tissue type; green: peptides surviving digestion with the lowest afﬁnity.study, T. gondii antigens were identiﬁed by using the results from
previous studies on the immunization of mice with plasmids coding
for speciﬁc T. gondii antigens.18–21 The afﬁnities were determined for
all 8-, 9-, and 10-mer peptides in the antigens for their binding to
MHC-I molecules. The correlation between the afﬁnity of the
peptides and data obtained on the survival of mice after
immunization and challenge in the present study was then analyzed.
The hypothesis was that antigens containing peptides with high
afﬁnities are more immunogenic, thereby inducing a stronger CTL
response, and thus provide better protection against T. gondii
infection. This hypothesis was supported by correlations between
the survival of immunized animals and the presence of high-afﬁnity
epitopes in the antigens. If the analysis involved in silico predictions(A) Antigens with crystal structures in the Protein Data Bank (AMA1, MIC2, SAG1 and
A4, GRA7 and M2AP); these structures were predicted by the software (see Methods
rent antigens. Red: peptides with the lowest afﬁnity in the Db tissue type; orange:
fﬁnity in the Db tissue type; light blue: peptides with the highest afﬁnity in the Kb
Figure 4. Peptides tested for reactivity in peripheral blood mononuclear cells
isolated from Toxoplasma gondii-infected C57BL/6 mice in an ex vivo ELISPOT
assay;*p < 0.05, **p < 0.01.
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be obtained. Taken together, the present study clearly supports the
current algorithms for in silico prediction of MHC-I binding5 as
efﬁcient tools with the capability of identifying protective vaccine
epitopes. It is of note that these numbers were correlated with a hard
end-point in investigations on the protective capability of the DNA
vaccines, namely animal survival.
The ability of the algorithms to identify epitopes that would
stimulate IFN-g production in leukocytes from animals that had
been infected with T. gondii was also studied. Consistent with the
expectations, it was found that the peptides that induced the highest
IFN-g release had a low KD (i.e., high afﬁnity), such as PT7 and PT8.
However, not all peptides with a low KD induced a strong IFN-g
release, as exempliﬁed by peptides PT2, PT4, and PT19. All peptides
with a high KDvalue (i.e., low afﬁnity) released low amounts of IFN-g
(PT5, PT6, PT11, PT21, and PT22). Thus, the in silico analysis cannot
predict all T-cell epitopes, but can be used to restrict the number of
epitopes to be tested in vivo to those with a predicted low KDvalue. It
is generally recognized that the requirement for binding and
presentation by MHC-I molecules is by far the most selective event of
antigen processing and presentation.24,25 It is believed that if
peptides have a KD value below 500 nM, this indicates that they may
contain a CTL epitope.26,27
This study clearly demonstrated the potential of in silico
predictions to guide the synthesis of antigens that will stimulate
speciﬁc immune responses such as IFN-g release, as well as to
support broader outcomes such as host survival following
immunization and challenge. These ﬁndings are of importance,
not only to obtain protection against T. gondii infection, but also to
obtain protection against other pathogens presenting more overt
health challenges.
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